Evidence that nitric oxide inhibits vascular inflammation and superoxide production via a p47phox-dependent mechanism in mice

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 4, 2010, Pages 429-434

  Harrison, Craig B ^a   Drummond, Grant R ^a   Sobey, Christopher G ^a   Selemidis, Stavros ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Atherosclerosis; Endothelial dysfunction; Nitric oxide; Nox2; P47 phox; Superoxide; Vascular inflammation

Indexed keywords

ANGIOTENSIN II; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHORBOL DIBUTYRATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR INFLAMMATION; CONTROLLED STUDY; HYPERTENSION; INFLAMMATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; SYSTOLIC BLOOD PRESSURE; VASCULAR RING;

ANGIOTENSIN II; ANIMALS; AORTA; ATHEROSCLEROSIS; BLOOD PRESSURE; ENZYME INHIBITORS; GLYCOSYLATION; HYPERTENSION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NADPH OXIDASE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SUPEROXIDES; TIME FACTORS; VASCULAR CELL ADHESION MOLECULE-1; VASCULITIS;

EID: 77949900768     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05317.x     Document Type: Article

References (45)

1. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987 327 : 524 526.
2. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J. Clin. Invest. 1998 101 : 731 736.
3. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987 ii : 1057 1058.
4. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998 97 : 2494 2498.
5. d'Uscio LV, Smith LA, Katusic ZS. Hypercholesterolemia impairs endothelium-dependent relaxations in common carotid arteries of apolipoprotein E-deficient mice. Stroke 2001 32 : 2658 2664.
6. d'Uscio LV, Baker TA, Mantilla CB et al. Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2001 21 : 1017 1022.
7. Kauser K, da Cunha V, Fitch R, Mallari C, Rubanyi GM. Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 2000 278 : H1679 85.
8. Kuhlencordt PJ, Gyurko R, Han F et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001 104 : 448 454.
9. G-nitro-l-arginine methyl ester in vitro and in vivo. J. Pharmacol. Exp. Ther. 1993 267 : 1091 1099.
10. Nabah YNA, Mateo T, Cerdá-Nicolás M et al. l-NAME induces direct arteriolar leukocyte adhesion, which is mainly mediated by angiotensin-II. Microcirculation 2005 12 : 443 453.
11. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992 340 : 1111 1115.
12. Stary HC, Chandler AB, Glagov S et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994 89 : 2462 2478.
13. ω-nitro-l-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation 2002 106 : 1729 1735.
14. Dananberg J, Sider RS, Grekin RJ. Sustained hypertension induced by orally administered nitro-l-arginine. Hypertension 1993 21 : 359 363.
15. Yamashita T, Yamamoto E, Kataoka K et al. Apoptosis signal-regulating kinase-1 is involved in vascular endothelial and cardiac remodeling caused by nitric oxide deficiency. Hypertension 2007 50 : 519 524.
16. Nakata S, Tsutsui M, Shimokawa H et al. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation 2008 117 : 2211 2223.
17. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2005 25 : 29 38.
18. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004 84 : 1381 1478.
19. Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR. NADPH oxidases in the vasculature: Molecular features, roles in disease and pharmacological inhibition. Pharmacol. Ther. 2008 120 : 254 291.
20. Selemidis S. Suppressing NADPH oxidase-dependent oxidative stress in the vasculature with nitric oxide donors. Clin. Exp. Pharmacol. Physiol. 2008 35 : 1395 1401.
21. Brandes RP, Miller FJ, Beer S et al. The vascular NADPH oxidase subunit p47phox is involved in redox-mediated gene expression. Free Radic. Biol. Med. 2002 32 : 1116 1122.
22. Marumo T, Schini-Kerth VB, Fisslthaler B, Busse R. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation 1997 96 : 2361 2367.
23. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J. Biol. Chem. 1996 271 : 317 321.
24. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction Molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 2008 10 : 1713 1765.
25. Sorescu D, Weiss D, Lassegue B et al. Superoxide production and expression of Nox family proteins in human atherosclerosis. Circulation 2002 105 : 1429 1435.
26. Judkins CP, Diep H, Broughton BRS et al. Direct evidence for a role of Nox2 in superoxide production, reduced nitric oxide bioavailability and early atherosclerotic plaque development in ApoE-/- mice. Am. J. Physiol. Heart Circ. Physiol. 2009 Epub 16 October 2009; doi
27. Barry-Lane PA, Patterson C, van der Merwe M et al. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J. Clin. Invest. 2001 108 : 1513 1522.
28. Selemidis S, Dusting GJ, Peshavariya H, Kemp-Harper BK, Drummond GR. Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells. Cardiovasc. Res. 2007 75 : 349 358.
29. Duerrschmidt N, Stielow C, Muller G, Pagano PJ, Morawietz H. NO-mediated regulation of NAD(P)H oxidase by laminar shear stress in human endothelial cells. J. Physiol. 2006 576 : 557 567.
30. Johnston CI, Millar JA, Casley DJ, McGrath BP, Matthews PG. Hormonal responses to angiotensin blockade Comparison between receptor antagonism and converting enzyme inhibition. Circ. Res. 1980 46 : I128 34.
31. Jung O, Marklund SL, Geiger H, Pedrazzini T, Busse R, Brandes RP. Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: In vivo and ex vivo evidence from ecSOD-deficient mice. Circ. Res. 2003 93 : 622 629.
32. Gupte SA, Kaminski PM, George S et al. Peroxide generation by p47phox-Src activation of Nox2 has a key role in protein kinase C-induced arterial smooth muscle contraction. Am. J. Physiol. Heart Circ. Physiol. 2009 296 : H1048 57.
33. Dunn JS, Freed BM, Gustafson DL, Stringer KA. Inhibition of human neutrophil reactive oxygen species production and p67phox translocation by cigarette smoke extract. Atherosclerosis 2005 179 : 261 267.
34. Ross R. Atherosclerosis: An inflammatory disease. N. Engl. J. Med. 1999 340 : 115 126.
35. Kojda G, Laursen JB, Ramasamy S et al. Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial cell nitric oxide synthase: Contributions of NOS isoforms to blood pressure and heart rate control. Cardiovasc. Res. 1999 42 : 206 213.
36. Li J-M, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II Role of the p47phox subunit. J. Biol. Chem. 2003 278 : 12.
37. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol. Rev. 2006 86 : 747 803.
38. Rajagopalan S, Kurz S, Munzel T et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation Contribution to alterations of vasomotor tone. J. Clin. Invest. 1996 97 : 1916 1923.
39. Landmesser U, Cai H, Dikalov S et al. Role of p47phox in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002 40 : 511 515.
40. Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am. J. Cardiol. 2001 87 : 25 32.
41. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 1993 21 : 660 666.
42. Sanchez M, Lodi F, Vera R et al. Quercetin and isorhamnetin prevent endothelial dysfunction, superoxide production, and overexpression of p47phox induced by angiotensin II in rat aorta. J. Nutr. 2007 137 : 910 915.
43. Garcia GE, Brown MR, Wead LM, Braun S, Gabbai FB. Effect of reduction of nitric oxide on plasma and kidney tissue angiotensin II levels. Am. J. Hypertens. 1997 10 : 1103 1108.
44. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 1998 18 : 842 851.
45. Cybulsky MI, Iiyama K, Li H et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 2001 107 : 1255 1262.